GlassScriptPhysician profile
Michael Alan Millard
NPI 1285052035
$8,551.74
in general payments reported to CMS, 2019-2025
40 companies · $424 in 2025
The $424 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,155 · 2020: $731 · 2021: $1,931 · 2022: $650 · 2023: $1,542 · 2024: $1,119 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,084.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $1,452.47 | 2019-2020 | |
| Boston Scientific Corporation | $1,345.07 | 2019-2025 | Watchman Access System, Avvigo Guidance System, Opticross |
| Abbott Laboratories | $1,155.05 | 2019-2024 | Coroflow, Diamondback Peripheral, Cardiomems |
| Astellas Pharma US INC | $389.62 | 2019-2021 | |
| Abiomed | $328.83 | 2021-2023 | Impella |
| Amgen INC. | $301.18 | 2019-2025 | Repatha |
| Cardiovascular Systems INC. | $280.06 | 2021-2022 | |
| Penumbra, INC. | $269.32 | 2021 | |
| Inari Medical, INC. | $246.24 | 2021-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| E.R. Squibb & Sons, L.L.C. | $244.19 | 2019-2024 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $236.02 | 2019-2025 | Farxiga, Wainua |
| Pfizer INC. | $177.34 | 2019-2025 | |
| Scpharmaceuticals INC. | $165.51 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.53 | 2022-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $162.83 | 2022-2025 | Lifevest |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $150.42 | 2021-2024 | Xarelto |
| Medtronic, INC. | $138.64 | 2023-2024 | Symplicity G3, Onyx Frontier, Launcher |
| Surmodics, INC. | $130.99 | 2023 | Pounce Venous Thrombectomy System, Pounce Thrombectomy, Sublime Radial Access 018 Rx Pta Dilatation Catheter |
| Bayer Healthcare Pharmaceuticals INC. | $130.20 | 2022-2025 | |
| Asahi Intecc USA, INC. | $125.98 | 2023 | Asahi Ptca Guide Wire |
| Edwards Lifesciences Corporation | $113.80 | 2021-2024 | Sapien 3 Ultra Resilia |
| Merck Sharp & Dohme LLC | $94.27 | 2022-2023 | Verquvo |
| Sanofi-Aventis U.S. LLC | $90.93 | 2023-2024 | |
| Shockwave Medical, INC | $62.87 | 2022-2025 | |
| Chiesi USA, INC. | $60.80 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $60.14 | 2021-2023 | |
| Kiniksa Pharmaceuticals International, Plc | $59.39 | 2024 | Arcalyst |
| Philips North America LLC | $52.70 | 2023-2025 | Coronary Other |
| Stryker Corporation | $49.36 | 2025 | Flowtriever |
| Alnylam Pharmaceuticals INC. | $48.57 | 2023-2024 | |
| Kiniksa Pharmaceuticals, LTD. | $37.52 | 2023 | Arcalyst |
| Terumo Medical Corporation | $35.28 | 2025 | Metacross Otw, Heartrail, Angio-Seal |
| W. L. Gore & Associates, INC. | $33.78 | 2021 | |
| Novo Nordisk INC | $30.46 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Bridgebio Pharma, INC. | $30.35 | 2025 | Attruby |
| Actelion Pharmaceuticals US, INC. | $21.82 | 2021 | |
| Irhythm Technologies, INC. | $21.43 | 2024 | Zio Xt Patch, Zio Monitor |
| Portola Pharmaceuticals, LLC | $21.42 | 2020 | |
| Celgene Corporation | $18.00 | 2024 | Camzyos |
| Teleflex LLC | $14.36 | 2024 | Trapliner |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Millard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.